In Selected Patient Populations (886)
Patients with renal failure or liver disease
As expected from differences in routes of elimination, for patients with poor or no renal function, changes in terminal half-life of elimination were greatest for ofloxacin (increased from 8 to 37 h) and moderate for norfloxacin, ciprofloxacin, and enoxacin (increases ranged from 4 to 5 h to 8 to 9 h) (Table 5), while no changes occurred for pefloxacin (506). Clearance by hemodialysis was
14% or less of simultaneous plasma clearance for norfloxacin (223), ciprofloxacin
(708), ofloxacin (224), and enoxacin (546) and was 28% for pefloxacin (506).
Peritoneal dialysis also contributed minimally to clearance of ciprofloxacin (230,
691) and ofloxacin (504). For pefloxacin,
Patients with renal failure or liver disease
As expected from differences in routes of elimination, for patients with poor or no renal function, changes in terminal half-life of elimination were greatest for ofloxacin (increased from 8 to 37 h) and moderate for norfloxacin, ciprofloxacin, and enoxacin (increases ranged from 4 to 5 h to 8 to 9 h) (Table 5), while no changes occurred for pefloxacin (506). Clearance by hemodialysis was
14% or less of simultaneous plasma clearance for norfloxacin (223), ciprofloxacin
(708), ofloxacin (224), and enoxacin (546) and was 28% for pefloxacin (506).
Peritoneal dialysis also contributed minimally to clearance of ciprofloxacin (230,
691) and ofloxacin (504). For pefloxacin,